Researchers assessed the long-term effectiveness of tumor necrosis factor inhibitors (TNFis) in patients with psoriatic arthritis who were exposed to at least 1 TNFi.
Positive topline data were announced from the phase 3 SELECT-PsA 1 study of upadacitinib, a Janus Kinase (JAK) inhibitor, in adult patients with active psoriatic arthritis who have had an inadequate response to at least 1 nonbiologic disease modifying antirheumatic drug (DMARD).
Researchers evaluated the psychometric properties of 3 patient-reported outcomes, HAQ-DI, PCS12, and PsAID-FC to assess physical function in patients with psoriatic arthritis.
Using high-resolution peripheral quantitative CT, the researchers compared the bone structure and microstructure in the metacarpal heads among patients with psoriatic arthritis and healthy controls.
Expression of interleukin (IL)-17A and IL-17F and the functional response to these cytokines were found to be comparable in spondyloarthritis and rheumatoid arthritis synovitis.
Patients with psoriasis showed an increased risk for ESRD development although patients who received systemic anti-psoriasis agents did not, a nationwide cohort study reveals.
Researchers reported on the clinical response of a patient with psoriatic nail dystrophy and psoriatic arthritis who received treatment with tildrakizumab.
Researchers identified patients who were more likely to achieve the Clinical Disease Activity for Psoriatic Arthritis treatment targets of remission or low disease activity with apremilast, using a pooled analysis of the PALACE studies.
Researchers evaluated the risk for adverse events, including serious infections, among patients with self-reported psoriatic arthritis compared with those with psoriasis.
Researchers studied the effect of secukinumab on enthesitis resolution in patients with psoriatic arthritis, using pooled data from the FUTURE 2 and 3 trials.
